Overview
Ocaliva, approved by the FDA in 2016 for treating primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid, was voluntarily withdrawn from the U.S. market on September 23, 2025, by Intercept Pharmaceuticals after the FDA issued a safety communication highlighting serious liver injury risks in patients without cirrhosis [1].
The drug, sold as 5 mg and 10 mg tablets for $5,000–$10,000 per month, works by activating the farnesoid X receptor to reduce bile acid production, but post-marketing surveillance revealed cases of liver decompensation, failure, and death, even at low doses. The FDA’s alert, based on clinical trials and real-world data showing elevated liver enzymes and bilirubin in non-cirrhotic patients, prompted Intercept to halt U.S. sales while continuing availability in other countries with modified labeling.
No formal recall was issued, but the withdrawal affects ongoing prescriptions for approximately 10,000 U.S. patients, many of whom have experienced symptom rebound or required alternative therapies. Emerging class action lawsuits allege that Intercept downplayed risks in FDA submissions and marketing, violating consumer protection laws and causing financial and health harms. Plaintiffs seek damages for medical expenses, pain and suffering, and punitive awards for alleged negligence, with potential for multidistrict litigation as more patients report adverse events.
The withdrawal follows a 2024 FDA investigation into 17 cases of liver injury, including 5 deaths, linked to Ocaliva use in non-cirrhotic PBC patients, despite label warnings limiting it to combination therapy. The drug’s high cost and limited alternatives for PBC—a chronic liver disease affecting 1 in 10,000 people—have left patients vulnerable, with some facing liver transplants or experimental treatments.
Legal experts predict class actions will target Intercept’s clinical trial data manipulation claims, similar to the 2023 Zantac recall lawsuits, which settled for $1.4 billion over cancer risks. The plaintiff class could include thousands, with litigation focusing on supply chain transparency and mandatory post-market surveillance.
Affected Ocaliva Drug Details
The withdrawal affects:
- Ocaliva (Obeticholic Acid) Tablets: 5 mg and 10 mg oral tablets, prescribed for PBC in adults without cirrhosis, used in combination with ursodeoxycholic acid. Distributed nationwide through pharmacies from 2016 to September 2025, with NDC numbers 70610-100-1 (5 mg) and 70610-100-2 (10 mg) [1].
Patients can identify affected prescriptions by checking the bottle label for Ocaliva and consulting their pharmacist or doctor for discontinuation guidance. All lots remain available until supplies are depleted, but new prescriptions are prohibited.
Side Effects of Ocaliva
Ocaliva’s side effects, particularly in non-cirrhotic patients, include:
- Pruritus (itching), affecting up to 23% of users.
- Elevated liver enzymes (ALT/AST), indicating hepatotoxicity.
- Fatigue and abdominal pain, common in 10–15% of patients.
- Jaundice and hyperbilirubinemia, signaling liver stress.
- Severe liver decompensation, leading to failure or death in rare cases.
These effects arise from Ocaliva’s bile acid modulation, which can overwhelm the liver in patients without advanced fibrosis.
Symptoms of Ocaliva Side Effects
Patients experiencing Ocaliva-related liver injury may notice:
- Early Symptoms: Itching, fatigue, or mild abdominal discomfort within weeks of starting therapy.
- Liver Stress Signs: Yellowing of skin/eyes (jaundice), dark urine, or pale stools.
- Severe Indicators: Swelling in the abdomen or legs, confusion, or bleeding tendencies signaling decompensation.
- Advanced Complications: Nausea, vomiting, or sudden weight gain from liver failure.
- Emergency Symptoms: Severe pain, fever, or altered mental status requiring immediate care.
Symptoms often develop gradually, with costs for monitoring and treatment ranging from $1,000 for liver function tests to $100,000 or more for transplants.
Recall Remedy and Consumer Actions
Intercept Pharmaceuticals and the FDA recommend:
- Consult your doctor immediately if on Ocaliva without cirrhosis; do not stop abruptly without guidance.
- Monitor liver enzymes via blood tests every 1–3 months, or more frequently if symptoms arise.
- Switch to alternative PBC treatments like ursodeoxycholic acid or fibrates, covered under insurance.
- Report adverse events to the FDA MedWatch program at fda.gov/medwatch.
No refunds are available for dispensed medication, but patients can document prescriptions and symptoms for potential claims. The FDA’s alert, issued September 23, 2025, advises discontinuing Ocaliva in non-cirrhotic patients and resuming only under close monitoring.
- https://www.webmd.com/drugs/updates/ocaliva-pulled-us-market
- https://www.fda.gov/drugs/drug-safety-and-availability/serious-liver-injury-being-observed-patients-without-cirrhosis-taking-ocaliva-obeticholic-acid-treat
- https://www.healio.com/news/gastroenterology/20241220/ocaliva-down-but-not-out-for-pbc